A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve

Heart and Vessels

Volumn 23, Issue 4, 2008, Pages 286-288

  Yildiz, Fatih ^a   Kurtaran, Behice ^a   Çayli, Murat ^a   Candevir, Aslihan ^a   Sümbül, Zehra ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Drug interaction; Moxifloxacin; Warfarin

Indexed keywords

FRESH FROZEN PLASMA; HEPARIN; MOXIFLOXACIN; PENICILLIN G; WARFARIN;

AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANAMNESIS; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; BACTERIUM ISOLATION; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG WITHDRAWAL; ECCHYMOSIS; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE THERAPY; MALE; MITRAL VALVE PROSTHESIS; MITRAL VALVE REGURGITATION; OPEN HEART SURGERY; PHYSICAL EXAMINATION; PLASMA TRANSFUSION; PNEUMONIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTHETIC VALVE ENDOCARDITIS; PROSTHETIC VALVE THROMBOSIS; RETREATMENT; SIDE EFFECT; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; AZA COMPOUNDS; BIOPROSTHESIS; BLOOD COAGULATION; BLOOD COMPONENT TRANSFUSION; DRUG INTERACTIONS; ENDOCARDITIS; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MITRAL VALVE; QUINOLINES; WARFARIN;

EID: 48449092805     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-008-1050-0     Document Type: Article

References (17)

1. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R (2004) Safety profile of oral and intravenous moxifloxacin: Cumulative data from clinical trials and postmarketing studies. Clin Ther 26(7):940-950
2. Gavin JR, Kubin R, Choudhri S, Kubitza D, Himmel H, Gross R, Meyer JM (2004) Moxifloxacin and glucose homeostasis: A pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 27:671-686
3. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT (1998) Oral anticoagulants: Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 114Suppl:445-469
4. Jones CB, Fugate SE (2002) Levofloxacin and warfarin interaction. Ann Pharmacother 36(10):1554-1557
5. Ellis RJ, Mayo MS, Bodensteiner DM (2000) Ciprofloxacin-warfarin coagulopathy: A case series. Am J Hematol 63(1):28-31
6. Elbe DH, Chang SW (2005) Moxifloxacin-warfarin interaction: A series of five case reports. Ann Pharmacother 39(2):361-364
7. O'Connor KA, O'Mahony D (2003) The interaction of moxifloxacin and warfarin in three elderly patients. Eur J Intern Med 14:255-257
8. Oz BS, Asgun F, Oz K, Kuralay E, Tatar H (2007) Warfarin-induced skin necrosis after open heart surgery due to protein S and C deficiency. Heart Vessels 22(1):64-66
9. Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM (2000) Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust 172(12):600-605
10. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A (2007) Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines: Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 28(2):230-268
11. Stass H, Kubitza D (2001) Profile of moxifloxacin drug interactions. Clin Infect Dis 32(Suppl 1):47-50
12. Richards RK (1943) Influence of fever upon the action of 3,3-methylene bis-(4-hydroxoycoumarin). Science 97:313-316
13. Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41(9):1633-1652
14. Arnold LM, Nissen LR, Ng TM (2005) Moxifloxacin and warfarin: Additional evidence for a clinically relevant interaction. Pharmacotherapy 25(6):904-907
15. Andriole VT, Haverstock DC, Choudhri SH (2005) Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 28(5):443-452
16. Pea F, Furlanut M (2001) Pharmacokinetic aspects of treating infections in the intensive care unit: Focus on drug interactions. Clin Pharmacokinet 40(11):833-868
17. Stass H (1999) Interaction profile of moxifloxacin. Drugs 58(suppl 2):18-19